Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-MCBS Scorecards

ESMO MCBS  1000x150

The searchable portal provides a centralised location of cancer medicines that have been scored and published by ESMO.

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Scorecard
Bevacizumab Carboplatin + paclitaxel Paclitaxel and carboplatin (6 cycles) Incompletely resected stage III and stage IV ovarian cancer Gynaecological Malignancies Ovarian Cancer - Metastatic
3
Niraparib - Placebo Maintenance Gynaecological Malignancies Ovarian Cancer gBRCA Metastatic
3
Niraparib - Placebo Maintenance Gynaecological Malignancies Ovarian Cancer non-gBRCA HRD +ve Metastatic
3
Niraparib - Placebo Maintenance Gynaecological Malignancies Ovarian Cancer non-gBRCA Metastatic
3
Trabectedin Pegylated liposomal doxorubicin Pegylated liposomal doxorubicin 2nd line metastatic ovarian cancer (Platine sensitive) Gynaecological Malignancies Ovarian Cancer - Metastatic
2
Trabectedin Pegylated liposomal doxorubicin Pegylated liposomal doxorubicin 2nd line metastatic ovarian cancer (All) Gynaecological Malignancies Ovarian Cancer - Metastatic
3
Olaparib - Placebo Maintenance (Randomised phase II study) Gynaecological Malignancies Ovarian Cancer BRCA mutation Metastatic
3
Cediranib Chemotherapy Platinum-based chemotherapy + placebo and placebo maintenance Platinum-sensitive relapsed ovarian cancer Gynaecological Malignancies Ovarian Cancer - Metastatic
1
Pembrolizumab - Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 2mg/kg Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥1% Metastatic
5
Pembrolizumab - Docetaxel 2nd line after platinum-based therapy OR TKI (for EGFR/ALK Mutated) advanced NSCLC>1% tumour cell PD-L1 expression (all) Pembro 10mg/kg Thoracic Malignancies Non-small-cell Lung Cancer PD-L1 ≥1% Metastatic
5

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings